An Investigation on Function and Performance of a New Microprocessor Controlled Prosthetic Knee

January 30, 2026 updated by: Össur Iceland ehf

An Investigation on Function and Performance of a New Microprocessor-controlled Prosthetic Knee

This investigation aims to compare the functional performance of a new passive microprocessor-controlled Prosthetic Knee to subjects usual microprocessor-controlled prosthetic knee.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

The primary objective of this study is to evaluate the efficacy of the investigational device compared to other passive MPKs (Rheo Knee 4, C-leg 4, Genium, X3, Plié 3, Orion 3, Quattro, Allux) regarding satisfaction in descending activities for moderate to high active prosthesis users within the intended population for the investigational device.

Additionally, to evaluate the balance confidence, perception of safety and comfort in standing with the investigational device compared to other passive MPKs (Rheo Knee 4, C-leg 4, Genium, X3, Plié 3, Orion 3, Quattro, Allux).

In phase I the performance in descending activities will be compared to any other passive MPK and in phase II there will be a subgroup analysis comparing to hydraulic MPKs and Rheo Knee 3, specifically.

The test will be a non-randomized single group open label prospective repeated measures (ABA) design.

Amputees are a small proportion of the general population. The population group specified in the inclusion/exclusion criteria is a further subsample of amputees. For practical reasons, i.e. to achieve statistical power, it is therefore more feasible to use within-subject comparison rather than creating study arms to compare. Furthermore, as mobile amputees generally have and use a prosthetic device for their daily activities, within-comparison is feasible comparing to the subject's previous device.

All investigational activities will be conducted at prosthetic out-patient clinics.

As stated above the primary endpoint is Satisfaction on descending stairs, and the secondary endpoints are satisfaction on descending ramps, balance confidence and standing comfort in that respective order of significance. In addition, there are two exploratory endpoints on mobility and balance during ambulation.

Procedures:

i) Recruitment Potential subjects will be identified from the customer base of the Local Principal Investigator (LPI). LPI evaluates, based on previous experience of interaction with and servicing of patients, if a potential participant is cognitively capable. If a potential participant fits the inclusion and exclusion criteria the LPI will contact them via telephone. During the telephone call the LPI will verify if they are interested in participating in a study. If interest is expressed at this point they will answer some screening questions and if the eligibility criteria are met an appointment will be made for the clinical visit and signing of the ICF. Questions relating to the duration of the study, number of clinical visits required and the investigational device will be answered.

Potential risk of participating in the investigation will be explained to the subject at this point to the candidate for enrolment.

The LPI will communicate to the study monitor and sponsor co-investigator the number of users he has identified that meet the inclusion criteria and are willing to participate.

ii) Test procedure There are three scheduled study events. Three sites will be included in the study, 4-10 users will be recruited at each site. At the initial visit, the first study event, for each subject a researcher qualified to obtain informed consent will seat the subject and proceed as described.

Prior to fitting the subject will be asked to provide feedback on the current prosthesis, by filling in a set of questionnaires (Including background information) and perform functional tests. The users will be fitted within the standard methods of prosthetic fitting, alignment, introduction, training and walking on various terrain.

After initial fitting, subjects will receive standard training on the investigational device by a certified prosthetist (the LPI) with support from sponsor investigators. When training is complete, and subjects feel comfortable and safe they will leave the site on the investigational device to use as their primary prosthesis in their daily life for 3 weeks. During this 3 week period the LPI will be in weekly contact with subjects via telephone to check on any issues that may arise.

The second visit will be at three weeks after visit 1. During this visit subjects will complete the same functional tests and questionnaires as at visit 1 (excluding background information) on the investigational device, with the addition of a usability questionnaire. They will then be fitted back to their prescribed device.

The third visit will be three weeks later. During this visit subjects will complete the same functional tests and questionnaires as at visit 2 (excluding usability questionnaire) on their prescribed device, as well as completing a qualitative interview on their experiences with both microprocessor knee devices.

iii) Measurements and data collection The same questionnaires, consisting of three valid instruments (PEQ questions, PLUS-M and ABC), will be used and filled in at three separate points in time. Background information will be collected at baseline only, usability questionnaire at visit 2 only and qualitative interview at visit 3 only. An activity report will be generated from the investigational device at visit 2 and an activity report from subjects prescribed device at visit 3, if applicable.

Study Type

Interventional

Enrollment (Actual)

14

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Reykjavik, Iceland, 110
        • Ossur Motionlab
    • Indiana
      • Merrillville, Indiana, United States, 46410
        • Bionic P & O
    • Michigan
      • Bay City, Michigan, United States, 48708
        • Oakland Orthopedic appliances
    • Ohio
      • Perrysburg, Ohio, United States, 43551
        • Perry Prosthetics

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • 45Kg< body weight < 136Kg
  • Cognitive ability to understand all instructions and questionnaires in the study;
  • Unilateral TF/KD amputees that are regular prosthesis users for at least 3 months
  • Current MPK users (passive MPKs only)
  • Age ≥ 18 years
  • Willing and able to participate in the study and follow the protocol
  • Moderate to high active users (PLUS M T-score>4021)

Exclusion Criteria:

  • Users with stump pain
  • Users with socket problems
  • Pregnant Users
  • Users using Power Knee, Kenevo or mechanical knees as their prescribed prosthesis
  • Alignment that cannot be matched with the Rheo Knee 4 setup, as described in Instructions for use.
  • Osseointegration

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: NAVii
Users will be fitted with a new microprocessor-controlled prosthetic knee for 3 weeks to compare to their usual device.
Passive Microprocessor-controlled prosthetic knee

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Satisfaction During Stair Descent
Time Frame: for analysis data from visit 2 (3 weeks after visit 1) and visit 3 (3 weeks after visit 2) were used
A question from the Prosthesis Evaluation Questionnaire (PEQ) regarding the satisfaction of walking downstairs is answered; scale allows for values from 1 to 10 while 1 represents very low satisfaction and 10 high satisfaction. The analysis was done by using a Bayesian approach which presents the posterior distribution of effects between Visit 2 and visit 3. The parameter for analysis is the difference of the score between Visits 2 and 3. If scores in Visit 2 (subjects using the investigational device) were larger than in visit 3 (subjects using their prescribed device), the difference of Visit3 - Visit2 scores would be negative and would therefore support the corresponding hypotheses. The Median difference and range of the Confidence interval of the difference are reported in the outcome measure data table.
for analysis data from visit 2 (3 weeks after visit 1) and visit 3 (3 weeks after visit 2) were used

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Six Minute Walk Test
Time Frame: for the final analysis data from visit 2 (3 weeks after visit 1) and visit 3 (3 weeks after visit 2) were used
The Six Minute Walk test (6MWT) is a record of the distance traveled by a given patient at his or her self-selected walking speed over a period of six minutes. All that is required is a stopwatch and a walking corridor or track of known distance.
for the final analysis data from visit 2 (3 weeks after visit 1) and visit 3 (3 weeks after visit 2) were used

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Kurt N Gruben, CPO, Ossur Americas

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 15, 2022

Primary Completion (Actual)

September 30, 2022

Study Completion (Actual)

September 30, 2022

Study Registration Dates

First Submitted

August 29, 2022

First Submitted That Met QC Criteria

August 29, 2022

First Posted (Actual)

August 31, 2022

Study Record Updates

Last Update Posted (Actual)

February 2, 2026

Last Update Submitted That Met QC Criteria

January 30, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • CIP2022022514

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Amputation

Clinical Trials on NAVii

Subscribe